A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.

Also called NCT06323174

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 189 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06323174
Other papers using this trial's data
  • Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study The lancet. Diabetes & endocrinology, 2026-08 DOI, PubMed 42251860

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, China, Hungary, Italy, Poland, Saudi Arabia, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06323174. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-19 (actual); primary completion 2025-10-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Acronym
REIMAGINE 1
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06323174
Content hash
891234b453a8e4a1a17b0d416c27e50a8a04fd2affa1ba6afc8cdbf32b0bcea8